Black Diamond (BDTX) Up 9.4% Since Last Earnings Report: Can It Continue?
Black Diamond (BDTX) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
BDTX
Black Diamond Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$121.48M
P/E Ratio
—
EPS
$-0.75
Beta
3.31
52W High
$4.94
52W Low
$1.60
50-Day MA
$1.95
200-Day MA
$2.40
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
8.33
PEG Ratio
—
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-44.35M |
| Operating Margin | 0.00% |
| Return on Equity | -37.20% |
| Return on Assets | -19.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.67 |
| Price-to-Book | 1.26 |
| Price-to-Sales (TTM) | 2.11 |
| EV/Revenue | 0.739 |
| EV/EBITDA | 2.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $57.30M |
| Float | $52.60M |
| % Insiders | 0.65% |
| % Institutions | 72.53% |
Historical Volatility
HV 10-Day
51.94%
HV 20-Day
50.50%
HV 30-Day
51.27%
HV 60-Day
62.72%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($10.00 target)
2
Strong Buy6
Buy1
HoldLatest News
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D.
GlobeNewsWire9/2/2026Neutral
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
Black Diamond Therapeutics trades below cash value, offering a compelling risk/reward profile in precision oncology. Silevertinib, BDTX's lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR, targeting NSCLC patients underserved by legacy TKIs. Despite mega-cap competition, BDTX's $118M cash runway, potential non-dilutive milestone payments, and MasterKey platform underpin a Buy rating.
Seeking Alpha7/6/2026Positive
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
Zacks Investment Research5/27/2026Positive
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
Zacks Investment Research5/27/2026Positive
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
Zacks Investment Research5/27/2026Positive
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.
Zacks Investment Research5/25/2026Negative
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.
GlobeNewsWire5/22/2026Neutral
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study cohort.
MarketBeat5/21/2026Neutral
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass.
GlobeNewsWire5/19/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BDTX and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026